Keywords: Cancer, Drug Development, Preclinical, Diffusion Imaging, RelaxometryWhilst cancer immunotherapies have shown marked and durable tumour responses in some patients, the majority derive no benefit. Strategies are being exploited to enhance tumour responses to immuno-oncology agents, including pharmacological activation of the STING pathway to create a more inflamed microenvironment. Multi-parametric MRI revealed a dose-dependent increase in murine tumour ADC in response to a STING agonist that was associated with histologically confirmed increase in tumour cell death. An acute, transient increase in tumour R2*, consistent with vascular occlusion, was also found. ADC is a sensitive early imaging biomarker of tumour response to STING agonism.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords